Meet our IXINITY Ambassadors

    Kirstin - Nathan - Christian - Ricardo

    Here’s your chance to connect with our ambassadors, share your experiences, and hear how they navigate life with hemophilia B.

     

    Talk with Kirstin about her journey to diagnosis with hemophilia B.

    Speak with Kirstin to discuss how she got her treatment on track.

    Reach out to Kirstin and learn how she made advances for the community.

    Share your story with Nathan and learn how he works to stay active.

    Chat with Christian and share your experiences. Hear why he thinks hemophilia summer camp is so important.


    ¿Qué te motiva? ¿Qué te empuja a dar tu mejor versión? Permítenos presentarte a Ricardo. Envíanos un correo electrónico a HemophiliaB@medexus.com, y organizaremos una videollamada para que puedas compartir tu historia con alguien tan decidido como tú.

     

     

    TERMS & CONDITIONS

    You must be thirteen (13) years or older to enroll. If you are aged 13 to 18, you should get your parent’s or guardian’s permission before providing your personal information.

    Medexus Pharma, Inc. and companies working on its behalf may disclose the personal information you provide us to a third-party vendor in order to deliver the information you are requesting about Medexus, our services and programs, or other topics of interest. We may also share your information with regulatory authorities or contact you regarding market research opportunities.

    Your personal information will be processed and stored in electronic databases controlled by or on behalf of Medexus. We will not sell or transfer your personal information to any unrelated third party for marketing purposes without your express permission.

    To learn more about how your personal information is used or if you decide that you no longer want to receive information from Medexus, please visit www.ixinity.com/privacy-terms-of-use/.

    Hear more personal stories of those who were interested in changing their factor, and their IXperience in choosing to switch to IXINITY.

    Jeron's IXINITY Story

    Jeron's IXINITY Story

    Jeron & Orson: Shared IXperiences

    Jeron & Orson: Shared IXperiences

    Want to share your IXINITY story?

    INDICATIONS AND IMPORTANT SAFETY INFORMATION

    Expand

    What is IXINITY?

    IXINITY [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. Your healthcare provider may give you IXINITY for routine prophylaxis, for on demand treatment to control bleeding episodes or when you have surgery.

    IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

    IMPORTANT SAFETY INFORMATION for IXINITY

    • You should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.

    • You should tell your healthcare provider if you have or have had medical problems, take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies, have any allergies, including allergies to hamsters, are nursing, are pregnant or planning to become pregnant, or have been told that you have inhibitors to factor IX.

    • You can experience an allergic reaction to IXINITY. Contact your healthcare provider or get emergency treatment right away if you develop a rash or hives, itching, tightness of the throat, chest pain, or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.

    • Your body may form inhibitors to IXINITY. An inhibitor is part of the body's defense system. If you develop inhibitors, it may prevent IXINITY from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to IXINITY.

    • If you have risk factors for developing blood clots, the use of IXINITY may increase the risk of abnormal blood clots.

    • Call your healthcare provider right away about any side effects that bother you or do not go away, or if your bleeding does not stop after taking IXINITY.

    • The most common side effect that was reported with IXINITY during clinical trials was headache.

    • These are not all the side effects possible with IXINITY. You can ask your healthcare provider for information that is written for healthcare professionals.


    For more information about IXINITY, please see full Prescribing Information, including Important Patient Information.

    You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.